Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting

Journal of Affective Disorders

Volumn 150, Issue 3, 2013, Pages 868-871

  Coplan, Jeremy ^a   Gugger, James J ^a   Tasleem, Hina ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Janian Medical Care   (United States)

Author keywords

Anxiety disorders; Atypical antipsychotic agents; Extrapyramidal syndrome; Mood disorders; Tardive dyskinesia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; QUETIAPINE; VALPROIC ACID; ZIPRASIDONE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; PRIORITY JOURNAL; PSYCHIATRIST; STEREOTYPY; TARDIVE DYSKINESIA;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADHD; AIMS; ANXIETY DISORDERS; ATTENTION-DEFICIT HYPERACTIVITY DISORDER; ATYPICAL ANTIPSYCHOTIC AGENTS; EXTRAPYRAMIDAL SYNDROME; GAD; GENERALIZED ANXIETY DISORDER; MAJOR DEPRESSIVE DISORDER; MDD; METHYLPHENIDATE; MOOD DISORDERS; MPH; MS; MULTIPLE SCLEROSIS; OBSESSIVE-COMPULSIVE DISORDER; OCD; POST-TRAUMATIC STRESS DISORDER; PTSD; TARDIVE DYSKINESIA; TRD; TREATMENT-RESISTANT DEPRESSION;

ADULT; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MOOD DISORDERS; MOVEMENT DISORDERS; RETROSPECTIVE STUDIES; RISK; YOUNG ADULT;

EID: 84888372340     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.04.053     Document Type: Article

References (19)

1. Berman, R.M., Thase, M.E., Trivedi, M.H., Hazel, J.A., Marler, S.V., Mcquade, R.D., Carson, W., Baker, R.A., Marcus, R.N., 2011. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatric Disease and Treatment 7, 303-312.
2. Burt, D.R., Creese, I., Snyder, S.H., 1977. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196, 326-328.
3. Casey, D.E., 2004. Pathophysiology of antipsychotic drug-induced movement disorders. Journal of Clinical Psychiatry 65 (Suppl. 9), 25-28.
4. Chung, A.K., 2012. Atypical presentation of tardive dyskinesia associated with risperidone long-acting injection as maintenance treatment in bipolar affective disorder: a case report. Current Drug Safety 7, 21-23.
5. Correll, C.U., Schenk, E.M., 2008. Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry 21, 151-156.
6. Croxtall, J.D., Scott, L.J., 2010. Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 24 (245-262 10) 2165/11203830-000000000-00000.
7. Gentile, S., 2007. Extrapyramidal adverse events associated with atypical anti-psychotic treatment of bipolar disorder. Journal of Clinical Psychopharmacology 27, 35-45.
8. Ghaemi, S.N., Hsu, D.J., Rosenquist, K.J., Pardo, T.B., Goodwin, F.K., 2006. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30, 209-213.
9. Guy, W.A., 1976. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health Education and Welfare, Washington, DC.
10. Kapur, S., Seeman, P., 2001. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. American Journal of Psychiatry 158, 360-369.
11. Keck, P.E., Jr. Mcelroy, S.L., Strakowski, S.M., Soutullo, C.A., 2000. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. Journal of Clinical Psychiatry 61 (Suppl 4), 33-38.
12. Klawans, H.L., Goetz, C.G., Perlik, S., 1980. Tardive dyskinesia: review and update. American Journal of Psychiatry 137, 900-908.
13. Maytal, G., Ostacher, M., Stern, T.A., 2006. Aripiprazole-related tardive dyskinesia. CNS Spectrums 11, 435-439.
14. Meyers, B.S., Flint, A.J., Rothschild, A.J., Mulsant, B.H., Whyte, E.M., Peasley-Miklus, C., Papademetriou, E., Leon, A.C., Heo, M., 2009. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Archives of General Psychiatry 66, 838-847.
15. Nasrallah, H.A., Brecher, M., Paulsson, B., 2006. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Bipolar Disorders 8, 467-474.
16. Piccolo, I., Thiella, G., Sterzi, R., Colombo, N., Defanti, C.A., 1998. Chorea as a symptom of neuroborreliosis: a case study. The Italian Journal of Neurological Sciences 19, 235-239.
17. Rangel-Barajas, C., Silva, I., Lopez-Santiago, L.M., Aceves, J., Erlij, D., Floran, B., 2011. L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata. Neurobiology of Disease 41, 51-61.
18. Woods, S.W., 2003. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663-667.
19. Woods, S.W., Morgenstern, H., Saksa, J.R., Walsh, B.C., Sullivan, M.C., Money, R., Hawkins, K.A., Gueorguieva, R.V., Glazer, W.M., 2010. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. Journal of Clinical Psychiatry 71, 463-474.